GlaxoSmithKline (GSK)

United Kingdom
Pharmaceuticals Biotechnology and Life Sciences

Corporate Bias Rating

Expand Summary

Risk Level:

Rating - Danger
High Risk


GlaxoSmithKline scored an 85 on the 2023 Corporate Equality Index (CEI) from the Human Rights Campaign (HRC), a political stakeholder group. By complying with Human Rights Campaign’s controversial demands, GlaxoSmithKline (GSK) increases the risk of dividing employees, alienating customers and harming shareholders. The company covers transgender-related medical costs for its employees and their children and provides specific sexual orientation and gender identity-based benefits. It also uses sex and gender ideology criteria in employee recruitment, vendor selection, and philanthropic support. GSK forces employees to undergo multiple ideological trainings and uses its corporate funds and political influence to support controversial sex and gender ideologies, organizations, and legislation. GSK provides a benefits package for employees which covers travel/lodging costs for an abortion. The company supports the Equality Act and funds LGBTQ causes and organizations. GSK opposed various state and local legislation intended to protect parental rights, girls’ sports, bathroom facilities, and gendered spaces. The company is a member of the MCCA, indicating its focus on recruiting, retaining, and promoting employees based on race. GSK is a corporate partner of the National LGBT Chamber of Commerce and is a silver sponsor of Out & Equal. For these reasons, GlaxoSmithKline receives a High Risk rating.

Generate Reports